Production (Stage)
Kiora Pharmaceuticals, Inc.
KPRX
$3.08
-$0.01-0.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -116.30% | -86.17% | 40.77% | 15.00% | 820.00% |
| Total Depreciation and Amortization | 20.99% | 121.89% | -66.51% | -68.43% | -62.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 145.04% | -140.04% | -72.28% | -37.19% | -52.68% |
| Change in Net Operating Assets | -11,832.05% | 446.64% | 782.74% | -301.66% | 99.51% |
| Cash from Operations | -119.85% | 12.74% | 136.50% | -169.58% | 543.87% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -96.26% | 2,651.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | 100.15% | -1,313.05% |
| Cash from Financing | -- | 100.00% | -- | -95.78% | 2,871.08% |
| Foreign Exchange rate Adjustments | 119.80% | -161.78% | 306.29% | 124.31% | -88.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.07% | 37.36% | 63.23% | -645.81% | 1,215.56% |